ianalumab (VAY736) - Novartis
Efficacy and Safety of Ianalumab in Sjögren's disease - Long-term results from the NEPTUNUS extension study (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB14; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; No abstract available 
Clinical • Late-breaking abstract • Sjogren's Syndrome
https://acrconvergence2026.eventscribe.net/ajaxcalls/PresentationInfo.asp?PresentationID=1918207
 
Thomas Dörner, MD
 
Oct 16, 2026
 
Prev Next